#nephrology San Diego

[beardedshreekna-blog]

The Diet for Chronic Kidney Disease

The Diet for Chronic Kidney Disease

In this video, dietitian Christy Turner, MS, RD, at UC San Diego Health (http://health.ucsd.edu/nephrology) discusses key diet components to maintaining kidney function: limiting salt intake to help keep blood pressure at goal, eating the right amount of protein, and improving blood sugar control.

For more information about kidney…

[coolluminaryland-blog1]

Acute Kidney Injury Treatment Market to Expand at a CAGR of Around 8% During the Forecast Period

Acute Kidney Injury (AKI) Treatment Market: Number of Candidate Drugs Increasing

Increasing geriatric population, susceptible to acute kidney injury (AKI), has created pressure on researchers and scientists to develop appropriate treatment and therapeutics. Currently, there are around 40 candidate drugs, meant for acute kidney injury treatment, and most of them are in their final stage of approval. The increasing patient pool is another factor that makes the acute kidney injury treatment market a highly lucrative proposition. Considering the evolutions in this landscape, and the possibilities of substantial opportunities, Transparency Market Research, in its new study, offers a 360 degree analysis on the key factors likely to influence market growth.

Evolution of Acute Kidney Injury (AKI) Treatment

Acute kidney injury, formerly known as acute renal failure, emerged as a prominent disease after the Second World War. Since then, more emphasis has been laid on the types of therapeutics that need to be developed that can effectively treat this ailment. Alkaline phosphatase, gemigliptin, and QPI002 are few therapeutics that are under clinical trial for treating AKI. As research on acute kidney injury gains momentum, new opportunities are likely to emerge. Influenced by a host of multi-pronged factors, the market for acute kidney injury treatment is likely to surpass a valuation of US$ 2.5 billion by the end of 2027.

Identify the key factors that will drive your company’s growth. Request a brochure Acute Kidney Injury Treatment Market

The Therapeutic Landscape

Adoption of AKI Biomarkers

The adoption of advanced technologies plays a vital role in enhancing healthcare services. Currently, treatment provided for acute kidney injury is undergoing substantial changes, as researchers are using advanced new tools, predictive models, and biomarkers to improve dialysis procedures and stymie development of acute kidney injuries at an early stage. Emphasis is given on risk stratification along with AKI biomarkers that will enhance overall treatment.

Ultrasound Technique – A Traditional Break Through

Introduction of new ultrasound techniques is expected to provide better treatment for acute kidney injuries and chronic kidney diseases. As ultrasound technique is non-invasive, cost-effective, and offers simple imaging modality, it has opened new avenues for monitoring, diagnosis, and treating acute kidney injury. Ultrasound is capable of reducing the effect of AKI by encouraging the splenic cholinergic anti-inflammatory pathway. Further developments are also being made to enhance sensitivity and specificity of ultrasound that will result in providing precise results of diagnosing kidney disease.

Want to know more such detailed insights of Acute Kidney Injury Treatment Market? Request a PDF sample Acute Kidney Injury Treatment Market

Market Players Collaborating with Research Institutes to Develop Effective Drugs

Researchers are engaged in studying different therapeutics that can be considered to treat AKI. Recently, researchers from the University of Alabama at Birmingham School of Medicine (UAB) and University of California San Diego School of Medicine received grants to enrich the skills especially for kidney diseases. The focus of the center is to evaluate kidney injury and function to improve diagnosis through several biomarkers. They also aim to identify targets for intervention and benefit in decision-making for physicians that will help in better management of patients with kidney diseases. Stakeholders in the acute kidney injury treatment market are keeping an eye on the results of these findings, as research and development remains a key success differentiator in this market. The go-to market strategies in this landscape are heavily influenced by the successful outcomes of research and development, and a substantial pie of the overall revenue share of stakeholders is spent on new product development. Therefore, industry-institution collaboration is likely to remain a norm rather than the exception in this market.

Vendors are making significant investments in research and development activities to develop drugs and treatment options for acute kidney injury. As mentioned earlier, as of now, there is no particular drug available in the market to treat AKI; therefore, research institutions and market participants are collaborating to develop drugs effective to treat acute kidney injury. At present, there are approx. 40 candidate drugs for AKI in different stages of development. Recently, Alloksys Life Sciences has developed therapeutic RESCAP®. This therapeutic drug is based on Alkaline Phosphatase (AP), a naturally available protein in the body. The aim of this therapeutic is to maintain Blood Brain Barrier (BBB), Kidney Glomerulus Barrier (KGB), Gut Barrier (GB), Lung Alveolar Barrier (LAB), and Placental Barrier (PB).

Expanding operations in future? To get the perfect launch ask for a custom report of Acute Kidney Injury Treatment Market

Moreover, LG Chem is also engaged in extensive research and development activities related to acute kidney injury treatment. LG Chem’sZemiglo is currently undergoing a clinical trial, and after gaining approval, it can be used to treat patients suffering from acute kidney injury. The development of these drugs will be beneficial for players, service providers, and patients. Market players will be capable of establishing themselves in a much profound manner, as most of drugs are in the final stage of approval. Hospitals and patients (end consumer) will also benefit largely from these developments. As the demand for specific drugs will be high in hospitals, and it can benefit both, the manufacturer and the hospital.

Mergers and Acquisitions: A Key Strategy

North America, led by the US, continues to be one of the leading markets for acute kidney injury treatment in the US. Leading companies are headquartered in this region, which makes it a prime location for research and development in this landscape. The presence of key players engaged in the development of novel drugs has meant that opportunities for manufacturers are high in the US and Canada as compared to markets where fewer companies are involved in research and development. The availability of new acute kidney injury products, such as QPI-1002 and Zemiglo along with innovative techniques are acting as a key contributor for market’s growth. Moreover, a large number of dialysis centers are present in the region (nearly 6,500 dialysis facilities in the United States alone, as per data by the National Kidney Foundation).

Mergers and acquisitions are another key strategy used by market players operating in the global acute kidney injury market. Recently, Fresenius Medical Care acquired 70% share of Chinese kidney hospitals and dialysis clinics – Guangzhou KangNiDaiSi Medical Investment Co., Ltd., mainly to expand its dialysis care network and to tap huge patient with kidney injury in this region. This acquisition will also trigger the development of dialysis centers with enhanced services in China. According to the Chinese Society of Nephrology, there are about 500,000 patients in China currently undergoing dialysis. This makes China the biggest market globally after the United States in terms of numbers.

Prevalence of acute kidney injury has grown substantially in Asia Pacific region–according to various studies, in South-East Asia, the AKI incidence was up to 18%~24% due to rising prevalence of malaria, leptospirosis, gastrointestinal tract infection, and monsoon climate. Moreover, in China the AKI incidence, misdiagnosis, and mortality rates were 1%-2%, 74.2%, and 12.4% respectively among hospitalized patients (2015). Thus, growing incidence of AKI has made government to develop supportive policies to treat acute kidney injury.

Governments in various countries are introducing supportive policies to spread awareness and provide better facilities to treat AKI. Higher prevalence of chronic kidney diseases (CKD) and growing interest in nephrology led to the initiation of The Kidney Disease Screening and Awareness Program (KDSAP) developed by Harvard College. A few years back, the Indian government started the National Dialysis Programme, under the National Health mission, an initiative of the Ministry of Health and Family Welfare. This initiative was carried out with the help of public-private partnerships at various hospitals. The aim was to provide life-saving procedure close by for patients, and to minimize the burden created by high medical costs.

[closethead9-blog]

ASN Announces Release of 'Roadmap' to Improve RRT - Renal and Urology News

October 25, 2018

The following article is part of conference coverage from Kidney Week 2018 in San Diego hosted by the American Society of Nephrology. Renal & Urology News staff will be reporting live on medical studies conducted by nephrologists and other specialists who are tops in their field in acute kidney injury, chronic kidney disease, dialysis, transplantation, and more. Check back for the latest news from Kidney Week 2018.

SAN DIEGO—In conjunction with its Kidney Week 2018 conference now in progress, the American Society of Nephrology (ASN) announced the release of its “Technology Roadmap for Innovative Approaches to Renal Replacement Therapy.”

A team led by Joseph V. Bonventre, MD, PhD, Chief of the Renal Unit and Director of the Bioengineering Division at Brigham and Women's Hospital in Boston, developed the roadmap as part ASN's Kidney Health Initiative (KHI). The objective is to improve to encourage industry, academic institutions, and other organizations to invest in and develop novel patient-driven alternatives to dialysis as renal replacement therapy (RRT), according to an ASN press release.

Among other components, the roadmap encourages multidisciplinary collaboration and multiple potential solution pathways with milestones and time projections.

“Creating innovative advanced therapies for those in renal failure is critically important. We owe it to our patients,” Dr Bonventre said in the release, adding that a key part of the roadmap is regulatory agency involvement.

Much of the roadmap is devoted to strategies for improved patient quality of life. The 34-page roadmap document identifies specific areas that need attention, including minimizing impact and intrusion of therapy on family and social life, improved ability to work and travel, increased mobility and physical activity, increased treatment choices, more liberal diet and fluid regulation, reduced medication burden, decreased disease- and treatment-related complications, decreased disease maintenance and interventions, and decreased financial impact. To address these issues, the roadmap identified the following areas for research and development: enhanced dialysis, portable or wearable devices, biohybrid and implantable technology, and kidney tissue regeneration.

Established in September 2012 under a Memorandum of Understanding between ASN and the FDA, the KHI Initiative includes more than 90 organizations. KHI members include biotechnology and pharmaceutical firms, device manufacturers, dialysis providers, foundations, patient and health professional organizations, research institutions, plus US and international government agencies, according to the release.

Reference

Technology Roadmap for Innovative Approaches to Renal Replacement Therapy. American Society of Nephrology. August 2018. 

Source: https://www.renalandurologynews.com/kidney-week-2018/asn-announces-release-of-roadmap-to-improve-rrt/article/810246/

[medicaleventsguide]

AKI & CRRT 2019 has been organised by CRRT Online at San Diego, California, United States Date: 26 Feb - 1 March 2019 We are dedicated to keeping our members up-to-date on the developments in Critical Care Nephrology. Supportive therapies for the management of critically ill patients continue to evolve as we gain new knowledge of the pathophysiology of multiorgan failure. Continuous Renal Replacement Therapies continue to define a platform to launch novel methods of extracorporeal support. Read more: https://ift.tt/2zYJ1XU #medicaleventsguide #medicalevents #medicalconference #healthcareevents #healthcareconference

[azveille]

La linagliptine semble efficace sur l'albuminurie chez des insuffisants rénaux diabétiques

L'antidiabétique linagliptine (Trajenta*, Boehringer Ingelheim/Lilly) a réduit la progression de l'albuminurie, avec un bon profil cardiovasculaire, chez des patients atteints à la fois d'un diabète de type 2 et d'une maladie rénale chronique, selon des données présentées au congrès de l'American Society of Nephrology (ASN), qui s'est achevé dimanche à San Diego.

Ces résultats, présentés vendredi en session orale late-breaking de la Kidney Week, sont issus de l'essai de phase IV CARMELINA dont l'objectif principal était d'évaluer la sécurité cardiovasculaire de la linaglitpine (cf dépêche du 19/07/2018 à 18:52).

Pour cette étude, 6.979 diabétiques de type 2 à haut risque cardiovasculaire avaient été inclus et la majorité présentaient une maladie rénale. Ils présentaient soit un rapport albumine/créatinine urinaire (ACR) supérieur à 30 mg/g et une maladie cardiovasculaire, soit un débit de filtration glomérulaire estimé (DFGe) de 45-75 nL/min/1,73m² et un ACR supérieur à 200 mg/g, soit un DFGe de 15-45 nL/min/1,73 m² sans critère d'ACR.

Ils présentaient en moyenne un taux d'hémoglobine glyquée (HbA1c) de 8% et un DFGe de 54,6 nL/min/1,73 m². Ils étaient 43% à avoir un DFGe égal ou inférieur à 45 nL/min/1,73 m² et 80% un ACR d'au moins 30 mg/g.

Les patients ont été randomisés entre la linagliptine à 5 mg et un placebo puis suivis pendant 2,2 ans en médiane.

Globalement, des événements cardiovasculaires (décès cardiovasculaire, infarctus du myocarde non fatal ou accident vasculaire cérébral non fatal) sont survenus chez 12,4% des patients traités par linagliptine, contre 12,1% dans le groupe placebo, soit une différence non statistiquement significative.

Un déclin de la fonction rénale était observé chez 9,4% des patients sous linagliptine contre 8,8% dans le groupe placebo, selon le résumé de la communication.

Sur les marqueurs clés de la fonction rénale, les résultats montrent que la pente du DFGe n'a pas été affectée chez les patients traités par linagliptine par rapport au groupe placebo, de respectivement -2,459 et -2,284, sans différence significative.

En revanche, il apparaît que la progression de l'albuminurie a touché moins de patients traités par linagliptine (35,3%) que dans le groupe placebo (38,5%), soit une réduction significative de 14%.

Les autres paramètres rénaux, comme le risque d'arriver au stade terminal de la maladie rénale chronique ou de décéder de la maladie rénale chronique, étaient similaires dans les deux groupes.

[kidneystories2013]

Here at Kidney Week 2018 with about 7,000 of my peeps from the American Society of Nephrology. Honored and humbled to be on faculty. #AAKPforpatients #patientchoicematters #KidneyHealthInitiative (at San Diego, California) https://www.instagram.com/p/Bpb6Y1BHAET/?utm_source=ig_tumblr_share&igshid=m55yxo06rgjc

[randybenedict]

Fresenius Medical touts Crit-Line hemodialysis fluid management studies

Fresenius Medical Care‘s (NYSE:FMS) renal therapies group today released results from four studies of its Crit-Line monitor that looked to explore the relation between relative blood volume monitoring (RBV-M) and patient outcomes.

Data from the studies were presented at the 2018 American Society of Nephrology’s Kidney Week Symposium in San Diego, Calif.

Results from two of the studies indicated that managing fluid with RBV-M resulted in reduced hospitalizations for patients new to hemodialysis, and provided a “positive return on investment,” according to a press release.

A retrospective database analysis of 1,068 incident hemodialysis patients indicated that there was a reduction of between 4.7 and 5.8 hospital days per year when RBV-M was used to manage fluid removal. The analysis examined data from incident patients at nine Renal Research Institute dialysis facilities between 2009 and 2017, Fresenius said.

In a separate economic model, RBV-M fluid management with Crit-Line was shown to reduce treatments and provide a positive return on investment within the first year, the company said.

“Active monitoring of relative blood volume can impact hospitalizations and missed treatments, helping fulfill our primary goal to improve the quality of life for patients with kidney failure. These new studies highlight the benefits of using a device like Crit-Line to improve dialysis treatments and lower overall healthcare costs,” renal therapies group prez Mark Costanzo said in a press release.

Earlier this month, Fresenius saw shares drop approximately 17% after it cut its outlook for the rest of the year on lower-than-expected third-quarter results.

The post Fresenius Medical touts Crit-Line hemodialysis fluid management studies appeared first on MassDevice.

from MassDevice https://ift.tt/2ENKxRr

[pharmamktnet]

AstraZeneca to Present New Data Demonstrating Breadth of Research Portfolio in Renal Disease at ASN Kidney Week 2018

AstraZeneca to Present New Data Demonstrating Breadth of Research Portfolio in Renal Disease at ASN Kidney Week 2018

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca will present new research spanning the Company’s Cardiovascular, Renal and Metabolism (CVRM) therapy area at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in San Diego, US, October 23-28, 2018.

ASN Kidney Week is a landmark meeting for AstraZeneca, which will provide new and in-depth research aiming to inform clinical practice…

[mikemortgage]

Klick Health Deepens Medical Strategy Bench to Support Huge Growth

NEW YORK & TORONTO — Klick Health today announced the arrival of seasoned medical strategy and market access experts to further bolster its growing team. This latest news follows a number of recent additions to Klick’s award-winning creative team and Klick’s industry-leading placement on Medical Marketing & Media (MM&M) magazine’s Agency 100 list, which recognizes the top agencies in the pharma, healthcare, and wellness industry.

“We’re building a top-notch team that leverages scientific data and data science that can stay ahead of healthcare and scientific trends to best approach medical communications and strategy,” said Holly Henry, Chief Medical Officer at Klick. “With our strong medical presence, prizewinning creative, and proven digital backbone, we create advanced communications that resonate with a wide array of patients and healthcare professionals.”

The independent agency, which had a record-breaking year in 2017 and is continuing its upward momentum and success in 2018, confirmed the following three appointments to help further support its clients:

Joseph Barbagallo, SVP, Medical Strategy

A board-certified, licensed physician, Joseph Barbagallo, MD, joins Klick with almost 16 years of experience in pharma advertising. Most recently, he served as EVP Director of Medical & Scientific Affairs at FCB Health, where he co-led the medical team in New York while heading up the NJ-based medical group at FCBCure. Previously, he worked at CDM New York for over six years overseeing a large team of medical directors and writers. Barbagallo has focused on many therapeutic areas, including cardiology, gastroenterology, metabolic disease, nephrology, neurology, psychiatry, and rheumatology, and continues to maintain his internal medicine board certification.

Jorge Durand, VP, Medical Strategy

Jorge Durand, PhD, brings almost a decade of industry expertise to Klick, most recently at TBWAWorldHealth as VP, Associate Medical Director. Prior, he worked at Corbett and Publicis Healthcare Group. Durand has a PhD in Biomedical Sciences and a Master’s degree in Nuclear Engineering and was previously involved in cardiovascular and metabolic research, as well as that of non-ionizing radiation effects.

Casey McCann, Director of Value, Access, and Reimbursement

With over 20 years of experience in healthcare communications Casey McCann joins Klick with a solid background in Market Access. Over the course of his career, he has successfully led brands at every stage of the product or portfolio lifecycle, including leading the launch of 15+ brands in many therapeutic categories within Professional, Consumer, Patient, and most extensively in the Managed Care sector. He has worked at multiple agencies, including IPG, Omnicom, and WPP and earned his MBA in Marketing & Advertising.

“We’re really excited to welcome Joseph, Jorge, and Casey to Klick and a culture that prioritizes people and exponential thinking and look forward to welcoming more of the industry’s brightest minds to our team,” added Henry.

A 2018 PM360 ELITE 100 award winner for her work in medical strategy, Henry has over 15 years of experience in pharmaceutical marketing and over eight years in scientific research. Before joining Klick in May 2017, she served as EVP Chief Medical Officer of the FCB Health Network, where she initiated, built, and grew the medical strategy group for almost seven years.

About Klick Health

Klick Health is the world’s largest independent, full-service marketing and commercialization agency for life sciences. By relentlessly conspiring with the future, Klick helps its clients outsmart and outpace disease so people can live richer, longer lives. Klick has been named Agency of the Year five times over the last six years by the industry’s leading publications and was recognized by the 2018 Cannes Lions Health Awards for its client campaigns. Follow Klick Health on Twitter at @KlickHealth.

About Klick Inc.

Klick operates with a fiercely independent spirit at the intersection of technology, creativity, and strategy. The Klick family is a diverse group of people who are driven and connected by a shared culture and commitment to the relentless pursuit of awesome at Klick Health, Katalyst, and Sensei Labs. Established in 1997, Klick has teams in Atlanta, Connecticut, Chicago, Los Angeles, New Jersey, New York, Philadelphia, San Diego, San Francisco, and Toronto. Klick has been consistently recognized as a leading Great Place to Work, Best Workplace for Women, Best Employer, Employee-Recommended Workplace, Fastest Growing Technology Company, and Best Managed Company. For more information on joining Klick, go to http://careers.klick.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180823005492/en/

Contacts

Klick Inc. Sheryl Steinberg, 416-214-4977 ext. 2412 VP, Communications pr@klick.com

from Financial Post https://ift.tt/2PxAWiI via IFTTT Blogger Mortgage Tumblr Mortgage Evernote Mortgage Wordpress Mortgage href="https://www.diigo.com/user/gelsi11">Diigo Mortgage

[distinguishedreviewtrash-blog]

CES 2017: The Well being And Health Devices Coming Your Means

CES 2017: The Well being And Fitness Gadgets Coming Your Approach

This product incorporates a smaller amount than what you'd need for a full bowel evacuation, and you'll, after per week or so, get used to the Magnesium CItrate and be regular again, however with better sleep. Additionally, the inclusion of methods to assist with issues of environmental complexity and to help meet the sensory needs of every child may also should be integrated in a complete program for these with ASD. It will require you to focus or relax as and when required. A Complement For Nerve Ache Relief will have a whole eye examination. I should say Danny has been doing fairly properly the previous couple of weeks. I do not want to gloat a lot as he'll discover out about and change it up, but he has been doing well lately. Av and i tested out the shock collar out so she feels what the dog feels if it should get shocked.

Now you will get that very same SLEEP magic in two tempting new flavors: Tangerine Dream and Mellow Mango. I've been fairly fortunate at getting Danny in on identical day appts, yay! I hope to see more from these researchers in the close to future! I’m sorry you missed this freebie, but please examine extra Free Samples at present available. I’m going to go on this just because I by no means have used this product. What was occurring in your mind earlier than this great match? This is a great opportunity for nephrology fellows to share their experiences with the nephrology community. Later this fall, the clinical heart plans to begin Schwartz Rounds, a forum where clinicians can talk about emotionally tough experiences at work. Tropical Storm Allison brought on some injury to the Texas Medical Center however the city was in a position to recuperate pretty quickly and thus did not result in important delays in affected person care.

Adams And Victor's Principles Of Neurology' has revealed over one hundred twenty manuscripts that replicate a variety of research pursuits from molecular facets of brain harm to the clinical care of head trauma patients. Mine. And the best way it affects me has changed over time. You’ve most likely heard or perceive the term “muscle memory:” it’s the best way you purchase new expertise by means of our body’s mechanistic means of encoding observe. Q: How does the fashionable office cause chronic stress in a manner that’s different from the previous? Sometimes, a small quantity of emotional relief can by directed at the panic assault sufferer by explaining that his panic attack signs are normally not “crazy, ” “insane, ” or even “irrational. What are the symptoms of a visual migraine? Since generally people are afraid to ask. Chiari malformation sort I develops as the skull and brain are growing. Is there evidence to help the off-label use of this drug to deal with my type of most cancers? If there was something you wanted say to your followers what would it be?

The situation when the blood vessel in the mind gets affected, it outcomes to cerebrovascular disorders. Outcomes from the EVOLVE trial using cinacalcet in ESRD printed in NEJM (33%)- Coming in at quantity three is the behemoth EVOLVE trial also introduced at ASN Kidney Week in San Diego this 12 months and revealed in NEJM. Hospitalist applications have emerged in tutorial medical centers to assist cope with the increasing case load-- I can hardly recall an educational Hospitalist program previous to 2003. Information From Hoofcare + Lameness in hospitalist applications continues to increase each year. Journal of Trauma & Dissociation, Current Medical Literature - Neurology and Neurosurgery,, Neurosurgery Quarterly, Journal of Neuroimmunology, Neuroimmunology and Neuroinflammation, Journal of Physiology, Journal of Neurophysiology, Journal of Clinical Neurophysiology, Neurophysiology. You probably have a severe medical situation, or history of coronary heart situations, All the time consult with a physician before utilizing any complement. Neurosurgeons can treat an array of situations, from back trauma to Parkinson's disease.

[coolluminaryland-blog1]

Acute Kidney Injury Treatment Market is Expected to Demonstrate a CAGR of 8% During the Forecast Period

Acute Kidney Injury (AKI) Treatment Market: Number of Candidate Drugs Increasing

Increasing geriatric population, susceptible to acute kidney injury (AKI), has created pressure on researchers and scientists to develop appropriate treatment and therapeutics. Currently, there are around 40 candidate drugs, meant for acute kidney injury treatment, and most of them are in their final stage of approval. The increasing patient pool is another factor that makes the acute kidney injury treatment market a highly lucrative proposition. Considering the evolutions in this landscape, and the possibilities of substantial opportunities, Transparency Market Research, in its new study, offers a 360 degree analysis on the key factors likely to influence market growth.

Evolution of Acute Kidney Injury (AKI) Treatment

Acute kidney injury, formerly known as acute renal failure, emerged as a prominent disease after the Second World War. Since then, more emphasis has been laid on the types of therapeutics that need to be developed that can effectively treat this ailment. Alkaline phosphatase, gemigliptin, and QPI002 are few therapeutics that are under clinical trial for treating AKI. As research on acute kidney injury gains momentum, new opportunities are likely to emerge. Influenced by a host of multi-pronged factors, the market for acute kidney injury treatment is likely to surpass a valuation of US$ 2.5 billion by the end of 2027.

Download Brochure Copy of Acute Kidney Injury Treatment Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=67523

The Therapeutic Landscape

Adoption of AKI Biomarkers

The adoption of advanced technologies plays a vital role in enhancing healthcare services. Currently, treatment provided for acute kidney injury is undergoing substantial changes, as researchers are using advanced new tools, predictive models, and biomarkers to improve dialysis procedures and stymie development of acute kidney injuries at an early stage. Emphasis is given on risk stratification along with AKI biomarkers that will enhance overall treatment.

Ultrasound Technique – A Traditional Break Through

Introduction of new ultrasound techniques is expected to provide better treatment for acute kidney injuries and chronic kidney diseases. As ultrasound technique is non-invasive, cost-effective, and offers simple imaging modality, it has opened new avenues for monitoring, diagnosis, and treating acute kidney injury. Ultrasound is capable of reducing the effect of AKI by encouraging the splenic cholinergic anti-inflammatory pathway. Further developments are also being made to enhance sensitivity and specificity of ultrasound that will result in providing precise results of diagnosing kidney disease.

Read Press Release of Acute Kidney Injury Treatment Market: https://www.transparencymarketresearch.com/pressrelease/acute-kidney-injury-treatment-market.htm

Market Players Collaborating with Research Institutes to Develop Effective Drugs

Researchers are engaged in studying different therapeutics that can be considered to treat AKI. Recently, researchers from the University of Alabama at Birmingham School of Medicine (UAB) and University of California San Diego School of Medicine received grants to enrich the skills especially for kidney diseases. The focus of the center is to evaluate kidney injury and function to improve diagnosis through several biomarkers. They also aim to identify targets for intervention and benefit in decision-making for physicians that will help in better management of patients with kidney diseases. Stakeholders in the acute kidney injury treatment market are keeping an eye on the results of these findings, as research and development remains a key success differentiator in this market. The go-to market strategies in this landscape are heavily influenced by the successful outcomes of research and development, and a substantial pie of the overall revenue share of stakeholders is spent on new product development. Therefore, industry-institution collaboration is likely to remain a norm rather than the exception in this market.

Vendors are making significant investments in research and development activities to develop drugs and treatment options for acute kidney injury. As mentioned earlier, as of now, there is no particular drug available in the market to treat AKI; therefore, research institutions and market participants are collaborating to develop drugs effective to treat acute kidney injury. At present, there are approx. 40 candidate drugs for AKI in different stages of development. Recently, Alloksys Life Sciences has developed therapeutic RESCAP®. This therapeutic drug is based on Alkaline Phosphatase (AP), a naturally available protein in the body. The aim of this therapeutic is to maintain Blood Brain Barrier (BBB), Kidney Glomerulus Barrier (KGB), Gut Barrier (GB), Lung Alveolar Barrier (LAB), and Placental Barrier (PB).

Expanding operations in future? To get the perfect launch ask for a custom report of Acute Kidney Injury Treatment Market

Moreover, LG Chem is also engaged in extensive research and development activities related to acute kidney injury treatment. LG Chem’sZemiglo is currently undergoing a clinical trial, and after gaining approval, it can be used to treat patients suffering from acute kidney injury. The development of these drugs will be beneficial for players, service providers, and patients. Market players will be capable of establishing themselves in a much profound manner, as most of drugs are in the final stage of approval. Hospitals and patients (end consumer) will also benefit largely from these developments. As the demand for specific drugs will be high in hospitals, and it can benefit both, the manufacturer and the hospital.

Mergers and Acquisitions: A Key Strategy

North America, led by the US, continues to be one of the leading markets for acute kidney injury treatment in the US. Leading companies are headquartered in this region, which makes it a prime location for research and development in this landscape. The presence of key players engaged in the development of novel drugs has meant that opportunities for manufacturers are high in the US and Canada as compared to markets where fewer companies are involved in research and development. The availability of new acute kidney injury products, such as QPI-1002 and Zemiglo along with innovative techniques are acting as a key contributor for market’s growth. Moreover, a large number of dialysis centers are present in the region (nearly 6,500 dialysis facilities in the United States alone, as per data by the National Kidney Foundation).

Mergers and acquisitions are another key strategy used by market players operating in the global acute kidney injury market. Recently, Fresenius Medical Care acquired 70% share of Chinese kidney hospitals and dialysis clinics – Guangzhou KangNiDaiSi Medical Investment Co., Ltd., mainly to expand its dialysis care network and to tap huge patient with kidney injury in this region. This acquisition will also trigger the development of dialysis centers with enhanced services in China. According to the Chinese Society of Nephrology, there are about 500,000 patients in China currently undergoing dialysis. This makes China the biggest market globally after the United States in terms of numbers.

Prevalence of acute kidney injury has grown substantially in Asia Pacific region–according to various studies, in South-East Asia, the AKI incidence was up to 18%~24% due to rising prevalence of malaria, leptospirosis, gastrointestinal tract infection, and monsoon climate. Moreover, in China the AKI incidence, misdiagnosis, and mortality rates were 1%-2%, 74.2%, and 12.4% respectively among hospitalized patients (2015). Thus, growing incidence of AKI has made government to develop supportive policies to treat acute kidney injury.

Governments in various countries are introducing supportive policies to spread awareness and provide better facilities to treat AKI. Higher prevalence of chronic kidney diseases (CKD) and growing interest in nephrology led to the initiation of The Kidney Disease Screening and Awareness Program (KDSAP) developed by Harvard College. A few years back, the Indian government started the National Dialysis Programme, under the National Health mission, an initiative of the Ministry of Health and Family Welfare. This initiative was carried out with the help of public-private partnerships at various hospitals. The aim was to provide life-saving procedure close by for patients, and to minimize the burden created by high medical costs.

[theresashell5-blog]

Postgraduate Study Admissions At The Educational institution Of Manchester.

Our experts asked several of our grads as well as trainees to share their experiences from studying in Molecular The field of biology and Medical at the College of Sheffield, as well as to inform our company what they've found yourself finishing with their degree. Even if you're currently functioning in your opted for field, certainly not possessing a college education and learning can easily stand between you and also development possibilities. But once enlisted, unpredicted monetary unexpected emergencies may oblige these pupils into make hard choices - leaving college, at times, is considered the only option. Banner - Educational institution Medical Center in Tucson positions one of the best in the nation for geriatrics as well as nephrology.

The element will certainly take a look at the function as well as functionality from international rule in making use of power between conditions as well as non-state actors. The Educational institution needs to supply the same services to expecting trainees that this supplies to various other students with short-lived disabilities. Over TWENTY percent from our pupils are actually doing graduate job. The University of Cambridge is actually the only UK college continually rated in the international top three universities for analysis and mentor. The component is going to permit students to consider the relevance, or even typically, from global law to present-day worldwide complications and to seriously examine its own constraints and impacts. If you are you looking for more on jagielonderby.info look at our own website. Humorously pertaining to the change as his quarter-life situation," Chen urged pupils to remain versatile when preparing their futures. If a training course brings in much more trainees compared to there are areas, pupils registered in the UW level plan are going to be actually provided priority over various other pupils, featuring exchange trainees. Bulleted checklists are actually fantastic for listings of skill-sets or enthusiasms however are necessarily limited in content as well as nuance, therefore have much less intensity in comparison to paragraphs. Coming from New Roo Weekend break by means of our Week from Welcome throughout the 1st days of training class, our most recent students are going to have a blast, learn their way around campus and also acquire great deals of good recommendations to reduce their switch to university life.

The Cheapest Technique To Make Your Free Ticket To gel.

Student selectivity for inbound freshers continuouslies be actually strongly very competitive, with a mean SAT credit rating of 1320; about fifty percent classed in the leading 5 percent of their senior high school lesson and 66 per-cent graduated in the leading 10 percent. Due to this there was actually some complication about which Comer Venue a trainee possessed courses in. Thereby, trainees started to use 'Mineral Industries Structure' so as to describe H.M. Arrival.

He acted as a postdoctoral other at the College of The golden state, San Diego, and at the University of California, San Francisco (UCSF) before coming to be Associate Research study Physiologist at UCSF. With its research study and other tasks, UF contributed greater than $12.56 billion to Florida's economic situation in fiscal year 2014-15.

The Past history from gel.

The Reason Why Everybody Passion gel.

Our 3,800 faculty consist of members of the National Institute of Sciences, the National Academy of Design, and also the Institute from Medication, plus the American Academy from Arts as well as Sciences, among other bodies. Starting along with a promotional treatment on writing and investigating American environmental history, the module is actually at that point divided right into 4 segments: Science as well as Relaxation, Doomsday Scenarios, Environmental Demonstration, as well as Consuming Mother nature. The importance in this module gones on just how economics can help our team to understand the culture we stay in. Furthermore, students have the opportunity to partner with renowned attendee artists for post degree residencies as well as professional training class. The training program is going to consist of a theoretical component in the course of which we will discover methods which our team could justify (or refuse) an ethical size to the method from law.

With over 6,000 first-year pupils anticipated, this will definitely be the most extensive training class since 1970. Wǝɫǝbʔaltxʷ - Intellectual House will definitely sustain trainees' capability to continue to be involved in their property people and also neighborhoods through its academic as well as social plans and its own symbolic concept. Take note, our team do not use italics for festivals, such as Open Cambridge, Festivity of Ideas and Open Cambridge.

State from Missouri Coordinating Panel of Higher Education. This is actually additionally some of several university buildings featured in the National Sign up of Historic Places. The Educational institution happily supplies Aviation service, Military as well as Naval force ROTC plans. The info as well as insight given up these pages is predominantly for the advantage of University of Kent grads and also trainees. They play a vital function within a Six Sigma campaign by baseding on Dark Waistbands' attempts of data assortment, review, method applying and style from practices. Undergraduate Admissions recruits would-be freshers as well as move pupils from in state, the southeast and nation broad and around the globe while strengthening or even maintaining premium.

[wcuijobs]

Ultrasound Technician Balboa Nephrology - San Diego, CA

Balboa Nephrology Medical Group is looking for a part-time Ultrasound Technician to join our growing team. This position operates sonographic equipment to perform diagnostic examinations and communicates results to interpreting physician. This position manages the daily operations of the sonographic area, equipment maintenance, reporting of equipment failures, and quality assessments (QA). 

Click below to view site

https://www.indeed.com/viewjob?jk=fa5cc572ec10f861&q=ultrasound+technician&l=California&tk=1blqptrd8bqki9pr&from=web

[azveille]

Diabète de type 2 : un nouvel inhibiteur du SGLT2 efficace dans la maladie rénale chronique modérée

Le nouvel antidiabétique oral inhibiteur du SGLT2 bexagliflozine, développé par Theracos, a montré une efficacité significative en traitement de patients diabétiques de type 2 présentant une maladie rénale chronique modérée, dans une étude présentée au congrès de l'American Society of Nephrology (ASN), qui s'est achevé dimanche à San Diego.

Ces résultats de phase III, présentés vendredi en session orale late-breaking de la Kidney Week, montrent que la bexagliflozine, un inhibiteur du cotransporteur sodium glucose de type 2 (SGLT2), diminue efficacement le taux d'hémoglobine glyquée (HbA1c) chez les patients diabétiques de type 2 atteints d'insuffisance rénale chronique modérée, tout en étant bien tolérée.

"L'hyperglycémie exacerbe la progression de la maladie rénale chronique et la plupart des médicaments hypoglycémiants ciblent rarement les morbidités associées à cette pathologie", rappellent Andrew Allegretti du Massachusetts General Hospital et ses collègues dans le résumé de la communication.

Ils ont évalué la bexagliflozine chez des diabétiques de type 2 insuffisants chroniques afin de déterminer si une fonction rénale altérée pouvait diminuer l'efficacité de ce traitement.

Leur étude a inclus 312 patients qui ont été randomisés entre un traitement par bexagliflozine à 20 mg/j et un placebo, pendant 24 semaines.

Globalement, la bexagliflozine a diminué le taux d'HbA1c de 0,37% par rapport au placebo. Pour les insuffisants rénaux de stade 3A et 3B, correspondant respectivement à un débit de filtration glomérulaire de 45 à 59 ml/min/1,73 m² et de 30 à 40 ml/min/1,73 m², le taux d'HbA1c a statistiquement diminué de respectivement 0,31% et 0,43% chez ceux traités par bexagliflozine par rapport au placebo.

Les chercheurs ont également observé une diminution significative du poids (1,61 kg), de la pression artérielle systolique (3,8 mmHg), de la glycémie à jeun (0,76 mmol/L) et de l'albuminurie (rapport de réduction moyen de 20,1%) chez les patients traités avec l'inhibiteur de SGLT2.

[ourrafaelhudson-blog]

In Vitro Diagnostics Market Size, Application Analysis, Growth Trends and Forecasts 2016 - 2022 - Brisk Insights

According to a recently published report, the In Vitro Diagnostics Market Is Expected To Grow At The Cagr Of 6.4% During 2015-2022. The segmentation of global in vitro diagnostics market is based on application, product & service, end user, technologyand geography. The report on global in vitro diagnostics market forecast, 2015-2022 (by application, product & service, end user, technology and geography) provides detailed overview and predictive analysis of the market.

Increasing prevalence of diabetes has increased the demand for IVD. Diabetes patients regularly use IVDs in order to monitor the blood glucose. According to WHO, the number of patients suffering from diabetes were 422 million and the prevalence rate of diabetes among adults was 8.5% in 2014. Rising demand for the point of care identification and detection of several infectious diseases such as viruses & bacteria causing upper and lower respiratory tract infections including RSV, influenza, legionnaires’ disease and pneumonia along with pathogens causing filariasis and malaria is one of the key factor driving the IVD market.

Full report available global in vitro diagnostics market forecast, 2015-2022 (by application, product & service, end user, technology and geography) report at http://www.briskinsights.com/report/in-vitro-diagnostics-market

The other key factors that are contributing significantly towards the growth of the market are the raising awareness for personalized medicine and the growth in geriatric population. Some of the challenges faced by in vitro diagnostics market are the stringent regulatory policies and the various reimbursement issues. As per the FDA's Federal Food Drug and Cosmetic Act, most genetic IVDs are of either Class II or Class III medical devices. In the case of Class III in vitro diagnostics, the manufacturers have to take approval from FDA before commercializing the IVD and meet some other stringent requirements.

SCOPE OF THE REPORT

1. GLOBAL IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2012 - 2022 ($ BILLION) 1.1. Infectious Diseases 1.2. Cardiology 1.3. Autoimmune Diseases 1.4. HIV/AIDS 1.5. Diabetes 1.6. Oncology/Cancer 1.7. Nephrology 1.8. Drug Testing 1.9. Other Applications

2. GLOBAL IN VITRO DIAGNOSTICS MARKET BY END USER 2012 - 2022 ($ BILLION) 2.1. Laboratories 2.2. Academic Institutes 2.3. Patient Self-Testing 2.4. Hospitals 2.5. Point-Of-Care Testing 2.6. Others

3. GLOBAL IN VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICE 2012 - 2022 ($ BILLION) 3.1. Instruments 3.2. Reagents & Kits 3.3. Data Management Software/Hardware 3.4. Services

4. GLOBAL IN VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2012 - 2022 ($ BILLION) 4.1. Hematology 4.2. Microbiology 4.3. Coagulation and Hemostasis 4.4. Clinical Chemistry 4.4.1. Electrolyte Panels 4.4.2. Lipid Profiles 4.4.3. Thyroid Function Panels 4.4.4. Basic Metabolic Panel 4.4.5. Liver Panels 4.4.6. Renal Profiles 4.4.7. Specialty Chemical Tests 4.5. Molecular Diagnostics 4.5.1. Polymerase Chain Reaction (PCR) 4.5.2. Microarrays 4.5.3. DNA Sequencing & Next-Generation Sequencing 4.5.4. Isothermal Nucleic Acid Amplification Technology (INAAT) 4.5.5. Hybridization 4.5.6. Others 4.6. Immunoassays 4.6.1. Radioimmunoassays (RIA) 4.6.2. Western Blot 4.6.3. Rapid Tests 4.6.4. Elispot 4.6.5. Elisa 4.6.5.1. Fluorescence Immunoassays (FIA) 4.6.5.2. Chemiluminescence Immunoassays (CLIAs) 4.6.5.3. Colorimetric Immunoassays (CI) 4.7. Others

Request Sample: http://www.briskinsights.com/sample-request/196

5. GLOBAL IN VITRO DIAGNOSTICS MARKET REGIONAL OUTLOOK 2012-2022 ( $ BILLION) 5.1. North America 5.2. Europe 5.3. Asia Pacific 5.4. Middle East & Africa 5.5. Latin America

6. COMPANY PROFILES 6.1. Abbott Laboratories, Inc. 6.2. Alere San Diego Inc. 6.3. Becton, Dickinson and Company 6.4. Biomérieux 6.5. Bio-Rad Laboratories, Inc. 6.6. Danaher Corporation 6.7. Elitech Group 6.8. Johnson and Johnson 6.9. Ortho Clinical Diagnostics, Inc. 6.10. Roche Diagnostics 6.11. Siemens Healthcare 6.12. Sysmex Corporation 6.13. Thermo Fisher Scientific Inc. 6.14. Transasia Bio-Medicals 6.15. Werfen Group

About Us :

Brisk Insights is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities optimize strategies. Working in a highly dynamic and multi-dimensional business makes decision making complex. Effective business decisions are a result of the synthesis of market information. Our Research and data analysis is an efficient and cost-effective way of providing robust market analysis and can yield highly valuable intelligence relating to consumers, competitors and markets.

Contact Us : Jennifer Smith Office 1094 109 Vernon House Friar Lane Nottingham United Kingdom NG1 6DQ Phone : +448081890034 (UK) Website : http://www.briskinsights.com/

[coolluminaryland-blog1]

Acute Kidney Injury Treatment Market to Expand at a CAGR of Around 8% During the Forecast Period

Acute Kidney Injury (AKI) Treatment Market: Number of Candidate Drugs Increasing

Increasing geriatric population, susceptible to acute kidney injury (AKI), has created pressure on researchers and scientists to develop appropriate treatment and therapeutics. Currently, there are around 40 candidate drugs, meant for acute kidney injury treatment, and most of them are in their final stage of approval. The increasing patient pool is another factor that makes the acute kidney injury treatment market a highly lucrative proposition. Considering the evolutions in this landscape, and the possibilities of substantial opportunities, Transparency Market Research, in its new study, offers a 360 degree analysis on the key factors likely to influence market growth.

Evolution of Acute Kidney Injury (AKI) Treatment

Acute kidney injury, formerly known as acute renal failure, emerged as a prominent disease after the Second World War. Since then, more emphasis has been laid on the types of therapeutics that need to be developed that can effectively treat this ailment. Alkaline phosphatase, gemigliptin, and QPI002 are few therapeutics that are under clinical trial for treating AKI. As research on acute kidney injury gains momentum, new opportunities are likely to emerge. Influenced by a host of multi-pronged factors, the market for acute kidney injury treatment is likely to surpass a valuation of US$ 2.5 billion by the end of 2027.

Identify the key factors that will drive your company’s growth. Request a brochure of this report here

The Therapeutic Landscape

Adoption of AKI Biomarkers

The adoption of advanced technologies plays a vital role in enhancing healthcare services. Currently, treatment provided for acute kidney injury is undergoing substantial changes, as researchers are using advanced new tools, predictive models, and biomarkers to improve dialysis procedures and stymie development of acute kidney injuries at an early stage. Emphasis is given on risk stratification along with AKI biomarkers that will enhance overall treatment.

Ultrasound Technique – A Traditional Break Through

Introduction of new ultrasound techniques is expected to provide better treatment for acute kidney injuries and chronic kidney diseases. As ultrasound technique is non-invasive, cost-effective, and offers simple imaging modality, it has opened new avenues for monitoring, diagnosis, and treating acute kidney injury. Ultrasound is capable of reducing the effect of AKI by encouraging the splenic cholinergic anti-inflammatory pathway. Further developments are also being made to enhance sensitivity and specificity of ultrasound that will result in providing precise results of diagnosing kidney disease.

Want to know more such detailed insights of Acute Kidney Injury Treatment Market? Request a PDF sample here

Market Players Collaborating with Research Institutes to Develop Effective Drugs

Researchers are engaged in studying different therapeutics that can be considered to treat AKI. Recently, researchers from the University of Alabama at Birmingham School of Medicine (UAB) and University of California San Diego School of Medicine received grants to enrich the skills especially for kidney diseases. The focus of the center is to evaluate kidney injury and function to improve diagnosis through several biomarkers. They also aim to identify targets for intervention and benefit in decision-making for physicians that will help in better management of patients with kidney diseases. Stakeholders in the acute kidney injury treatment market are keeping an eye on the results of these findings, as research and development remains a key success differentiator in this market. The go-to market strategies in this landscape are heavily influenced by the successful outcomes of research and development, and a substantial pie of the overall revenue share of stakeholders is spent on new product development. Therefore, industry-institution collaboration is likely to remain a norm rather than the exception in this market.

Vendors are making significant investments in research and development activities to develop drugs and treatment options for acute kidney injury. As mentioned earlier, as of now, there is no particular drug available in the market to treat AKI; therefore, research institutions and market participants are collaborating to develop drugs effective to treat acute kidney injury. At present, there are approx. 40 candidate drugs for AKI in different stages of development. Recently, Alloksys Life Sciences has developed therapeutic RESCAP®. This therapeutic drug is based on Alkaline Phosphatase (AP), a naturally available protein in the body. The aim of this therapeutic is to maintain Blood Brain Barrier (BBB), Kidney Glomerulus Barrier (KGB), Gut Barrier (GB), Lung Alveolar Barrier (LAB), and Placental Barrier (PB).

Expanding operations in future? To get the perfect launch ask for a custom report here

Moreover, LG Chem is also engaged in extensive research and development activities related to acute kidney injury treatment. LG Chem’sZemiglo is currently undergoing a clinical trial, and after gaining approval, it can be used to treat patients suffering from acute kidney injury. The development of these drugs will be beneficial for players, service providers, and patients. Market players will be capable of establishing themselves in a much profound manner, as most of drugs are in the final stage of approval. Hospitals and patients (end consumer) will also benefit largely from these developments. As the demand for specific drugs will be high in hospitals, and it can benefit both, the manufacturer and the hospital.

Mergers and Acquisitions: A Key Strategy

North America, led by the US, continues to be one of the leading markets for acute kidney injury treatment in the US. Leading companies are headquartered in this region, which makes it a prime location for research and development in this landscape. The presence of key players engaged in the development of novel drugs has meant that opportunities for manufacturers are high in the US and Canada as compared to markets where fewer companies are involved in research and development. The availability of new acute kidney injury products, such as QPI-1002 and Zemiglo along with innovative techniques are acting as a key contributor for market’s growth. Moreover, a large number of dialysis centers are present in the region (nearly 6,500 dialysis facilities in the United States alone, as per data by the National Kidney Foundation).

Mergers and acquisitions are another key strategy used by market players operating in the global acute kidney injury market. Recently, Fresenius Medical Care acquired 70% share of Chinese kidney hospitals and dialysis clinics – Guangzhou KangNiDaiSi Medical Investment Co., Ltd., mainly to expand its dialysis care network and to tap huge patient with kidney injury in this region. This acquisition will also trigger the development of dialysis centers with enhanced services in China. According to the Chinese Society of Nephrology, there are about 500,000 patients in China currently undergoing dialysis. This makes China the biggest market globally after the United States in terms of numbers.

Prevalence of acute kidney injury has grown substantially in Asia Pacific region–according to various studies, in South-East Asia, the AKI incidence was up to 18%~24% due to rising prevalence of malaria, leptospirosis, gastrointestinal tract infection, and monsoon climate. Moreover, in China the AKI incidence, misdiagnosis, and mortality rates were 1%-2%, 74.2%, and 12.4% respectively among hospitalized patients (2015). Thus, growing incidence of AKI has made government to develop supportive policies to treat acute kidney injury.

Governments in various countries are introducing supportive policies to spread awareness and provide better facilities to treat AKI. Higher prevalence of chronic kidney diseases (CKD) and growing interest in nephrology led to the initiation of The Kidney Disease Screening and Awareness Program (KDSAP) developed by Harvard College. A few years back, the Indian government started the National Dialysis Programme, under the National Health mission, an initiative of the Ministry of Health and Family Welfare. This initiative was carried out with the help of public-private partnerships at various hospitals. The aim was to provide life-saving procedure close by for patients, and to minimize the burden created by high medical costs.